{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:55:08Z","timestamp":1790290508382,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the characteristics, treatment and outcome of patients with immune thrombocytopenia with clinical significance (ITPCS) associated with SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective multicentre study included SLE patients who experienced \u22651 ITPCS (defined as ITP with attributable bleeding disorders and\/or a platelet count &amp;lt;30\u00d7109\/l). Other causes of secondary thrombocytopenia were excluded. Major bleeding event (MBG) was defined as Khellaf score\u2009&amp;gt;8 and\/or WHO score\u2009&amp;gt;2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 90 patients were included, the median (range) follow-up duration was 80 (6\u2013446) months. ITP was diagnosed before SLE in 25 patients. They presented a high rate of autoimmune haemolytic anaemia (15%), antiphospholipid antibody (62%) and antiphospholipid syndrome (19%). The 25 (28%) patients who experienced MBG had significantly more bleedings at ITP diagnosis and higher bleeding scores, and serositis and thrombosis during follow-up. They required significantly more treatment lines, transfusions and hospitalizations. The 11 (12%) patients who experienced no bleeding event presented a significantly more restricted SLE phenotype (cutaneous and\/or articular). Patients received a mean (range) of 4.2 (1\u201311) treatment lines. Corticosteroids and HCQ allowed ITPCS overall response in one-third of patients. The median relapse-free survival of rituximab (n\u2009=\u200934), AZA (n\u2009=\u200919), MMF (n\u2009=\u20098), thrombopoietin-receptor agonists (n\u2009=\u200916) and splenectomy (n\u2009=\u200919) were 53, 31.5, 61, 24.5 and 78\u2009months, respectively. Four patients experienced thrombotic events after splenectomy and one occurred under thrombopoietin-receptor agonist treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SLE-ITCS patients displayed a high rate of haematological abnormalities and MBG patients exhibited higher morbidity. Management of thrombocytopenia was highly heterogeneous and many options seem viable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab925","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T20:16:45Z","timestamp":1639426605000},"page":"3627-3639","source":"Crossref","is-referenced-by-count":37,"title":["Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients"],"prefix":"10.1093","volume":"61","author":[{"given":"Micka\u00ebl","family":"Roussotte","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hospices Civils de Lyon , Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Gerfaud-Valentin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospices Civils de Lyon , Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Hot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospices Civils de Lyon , Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Audia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Dijon , Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Dijon , Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thibault","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Dijon , Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-8432","authenticated-orcid":false,"given":"Herv\u00e9","family":"Lobbes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Clermont-Ferrand , Clermont-Ferrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Le Guenno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Clermont-Ferrand , Clermont-Ferrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radjiv","family":"Goulabchand","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Montpellier , Montpellier"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cathebras","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Saint Etienne , Saint Etienne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loig","family":"Varron","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier de Mont\u00e9limar , Mont\u00e9limar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier de Bourg en Bresse , Bourg en Bresse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Grenoble , Grenoble"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Compain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier de Chamb\u00e9ry , Chamb\u00e9ry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Baudet","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier d\u2019Annecy , Annecy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Karkowski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Militaire de Desgenettes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"P\u00e9rard","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier de St. Joseph St. Luc , Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Ebbo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier de La Timone , Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospices Civils de Lyon , Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospices Civils de Lyon , Lyon"},{"name":"Universit\u00e9 Claude Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), INSERM U1290 , Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"2022090108141903500_keab925-B1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garc\u00eda","year":"2016","journal-title":"J Autoimmun"},{"key":"2022090108141903500_keab925-B2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0268-960X(93)90006-P","article-title":"Haematological manifestations of systemic lupus erythematosus","volume":"7","author":"Keeling","year":"1993","journal-title":"Blood Rev"},{"key":"2022090108141903500_keab925-B3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjms.2019.03.002","article-title":"Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"357","author":"Chen","year":"2019","journal-title":"Am J Med Sci"},{"key":"2022090108141903500_keab925-B4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ard.2004.033100","article-title":"Lupus thrombocytopenia: clinical implications and prognostic significance","volume":"64","author":"Ziakas","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022090108141903500_keab925-B5","first-page":"4","article-title":"The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature","volume":"7","author":"Mohammadpour","year":"2018","journal-title":"J Res Pharm Pract"},{"key":"2022090108141903500_keab925-B6","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"key":"2022090108141903500_keab925-B7","doi-asserted-by":"crossref","first-page":"e2818","DOI":"10.1097\/MD.0000000000002818","article-title":"Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients","volume":"95","author":"Jung","year":"2016","journal-title":"Medicine"},{"key":"2022090108141903500_keab925-B8","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s10067-018-4312-y","article-title":"Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022090108141903500_keab925-B9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022090108141903500_keab925-B10","author":"Has-sante.fr","year":"2017"},{"key":"2022090108141903500_keab925-B11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.autrev.2017.04.011","article-title":"International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus","volume":"16","author":"Kleinmann","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2022090108141903500_keab925-B12","author":"Has-sante.fr"},{"key":"2022090108141903500_keab925-B13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022090108141903500_keab925-B14","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022090108141903500_keab925-B15","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"2022090108141903500_keab925-B16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/03007995.2011.644849","article-title":"Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia","volume":"28","author":"Fogarty","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2022090108141903500_keab925-B17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/annrheumdis-2020-217356","article-title":"Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or \u2018blood-dominant\u2019 lupus?","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022090108141903500_keab925-B18","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2022090108141903500_keab925-B19","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"2022090108141903500_keab925-B20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/0961203319877245","article-title":"Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival","volume":"28","author":"Art\u0131m-Esen","year":"2019","journal-title":"Lupus"},{"key":"2022090108141903500_keab925-B21","doi-asserted-by":"crossref","first-page":"e000078","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2022090108141903500_keab925-B22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2005.041673","article-title":"Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment","volume":"65","author":"Giannouli","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022090108141903500_keab925-B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"Unlu","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"2022090108141903500_keab925-B24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fimmu.2019.00885","article-title":"Opposite profiles of complement in Antiphospholipid Syndrome (APS) and systemic lupus erythematosus (SLE) among patients with Antiphospholipid Antibodies (aPL)","volume":"10","author":"Savelli","year":"2019","journal-title":"Front Immunol"},{"key":"2022090108141903500_keab925-B25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/annrheumdis-2020-217013","article-title":"Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study","volume":"79","author":"Zhu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022090108141903500_keab925-B26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022090108141903500_keab925-B27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"2022090108141903500_keab925-B28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"2022090108141903500_keab925-B29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5\u2009years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"key":"2022090108141903500_keab925-B30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.sla.0000133182.92780.9c","article-title":"Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus","volume":"240","author":"You","year":"2004","journal-title":"Ann Surg"},{"key":"2022090108141903500_keab925-B31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10067-018-3979-4","article-title":"Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis","volume":"37","author":"Barron","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022090108141903500_keab925-B32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijsu.2013.11.017","article-title":"Benefits and risks of splenectomy","volume":"12","author":"Weledji","year":"2014","journal-title":"Int J Surg"},{"key":"2022090108141903500_keab925-B33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/25785826.2019.1696644","article-title":"Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab","volume":"42","author":"Abe","year":"2019","journal-title":"Immunol Med"},{"key":"2022090108141903500_keab925-B34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/key072","article-title":"Thrombopoietin receptor agonist, splenectomy and intravenous immunoglobulin for immune thrombocytopaenia with systemic lupus erythematosus","volume":"57","author":"Sofue","year":"2018","journal-title":"Rheumatology"},{"key":"2022090108141903500_keab925-B35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00296-009-1207-x","article-title":"Splenectomy for thrombocytopenia associated with systemic lupus erythematosus in 11 Chinese patients","volume":"31","author":"Li","year":"2011","journal-title":"Rheumatol Int"},{"key":"2022090108141903500_keab925-B36","doi-asserted-by":"crossref","first-page":"e0198184","DOI":"10.1371\/journal.pone.0198184","article-title":"Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice","volume":"13","author":"Depr\u00e9","year":"2018","journal-title":"PLoS One"},{"key":"2022090108141903500_keab925-B37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/BOR.0000000000000599","article-title":"Treatment of primary and secondary immune thrombocytopenia","volume":"31","author":"Kado","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2022090108141903500_keab925-B38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"2022090108141903500_keab925-B39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1191\/0961203303lu417cr","article-title":"Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil","volume":"12","author":"Vasoo","year":"2003","journal-title":"Lupus"},{"key":"2022090108141903500_keab925-B40","first-page":"CD007746","article-title":"Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients","author":"Wagner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2022090108141903500_keab925-B41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1191\/0961203306lu2266oa","article-title":"Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus","volume":"15","author":"Quartuccio","year":"2006","journal-title":"Lupus"},{"key":"2022090108141903500_keab925-B42","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","article-title":"Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study","volume":"39","author":"Sun","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2022090108141903500_keab925-B43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semarthrit.2010.03.005","article-title":"Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review","volume":"40","author":"Letchumanan","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2022090108141903500_keab925-B44","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology"},{"key":"2022090108141903500_keab925-B45","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"key":"2022090108141903500_keab925-B46","doi-asserted-by":"crossref","first-page":"e11356","DOI":"10.1097\/MD.0000000000011356","article-title":"Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"2022090108141903500_keab925-B47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/CLEP.S105888","article-title":"Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US","volume":"8","author":"Cetin","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2022090108141903500_keab925-B48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology"},{"key":"2022090108141903500_keab925-B49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine1962.29.481","article-title":"Thrombocytopenia subsequently develops systemic lupus erythematosus can anti-SS-a antibody predict the next event?","volume":"29","author":"Adachi","year":"1990","journal-title":"Jpn J Med"},{"key":"2022090108141903500_keab925-B50","first-page":"321359","article-title":"Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects","volume":"2014","author":"Cozzani","year":"2014","journal-title":"Autoimmune Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab925\/41959981\/keab925.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3627\/45626701\/keab925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3627\/45626701\/keab925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T08:34:04Z","timestamp":1662021244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/9\/3627\/6463648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,12,16]]},"published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab925","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,12,16]]}}}